Cancer name Follicular Lymphoma
Cancer Type DLBC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Rituximab
Drugstatus Approved
Drugbank ID DB00073
Checkpoints NA
Signature Type Protein
Signature PD-1
Official Symbol PDCD1
Mode of action PROT_NR_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trail
Description On multivariate analysis, 4 risk factors were determined to be independent prognostic factors for decreased OS: age55 years or greater (HR, 2.77; 95% CI, 1.34-5.73;P= .006),bulky disease (HR, 2.27; 95% CI, 1.03-5.00;P= .04), CD68+ef-LAMs greater than 16.8 cells/HPF (HR, 2.15;95% CI, 1.14-4.06;P= .02), and PD-1+ T cells greater than35.6 cells/HPF (HR, 1.98; 95% CI, 1.09-3.60;P= .03).
PMID 21237493
Title Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma